Featured Trials

All clinical trials performed by IU Health Physicians strive to produce newsworthy and life-changing results. The trials below are the latest to achieve breakthrough discoveries.

Genetic Discover Between Breast Cancer and Neuropathy

Patients who receive chemotherapy as treatment for cancer can suffer from a list of side effects, one commonly being neuropathy, the damage to the peripheral nervous system causing pain, numbness, tingling, etc. to extremities. Dr. Bryan Schneider, a Simon Cancer Center physician and researcher discovered a genetic indicator in breast cancer patients, rooting the partial cause and source of neuropathy. Dr. Schneider and his IU Health team examined more than one million genetic variations in 2,204 patients who participated in the Eastern Cooperative Oncology Group clinical trial E5103, also learning genetic subgroups, age and race effect the likelihood of developing neuropathy. With this information, Dr. Schneider is continuing to research how to decrease the risk of neuropathy and prevention methods.

Ongoing Success in the Fight Against Melanoma

Melanoma, more commonly known as skin cancer, is becoming exponentially prevalent. Dr. Doug Schwartzentruber and his team of IU Health specialists first achieved notoriety in 2009, when their study was among the first to prove the benefits of vaccines against cancer. Building off this new knowledge, Dr. Schwartzentruber et. al, implemented research in trial participants learning a cancer vaccine can shrink tumors and slow potential cancer growth. This is the first vaccine study in any cancer field proving benefits in a clinical trial. One hundred and eighty-five patients at more than 21 sites participated in the trial, increasing their median overall survival rate from 11.1 months to 17.8 months. Dr. Schwartzentruber was awarded a position on TIME Magazine’s 2010 list of the 100 Most Influential People in the World for his discoveries.

Educational Collaboration Leads to Cancer Clinical Trial

IU Health, in their unique partnership with universities across the state, is afforded the opportunity to capitalize and fund student research. Recently, a team of Purdue University students and faculty began researching a more effective procedure for prostate cancer detection to be tested in a clinical trial by the IU School of Medicine and IU Health Simon Cancer Center. The test will aim to increase the radio-imaging and detection of prostate cancer cells in patients, decreasing the likelihood of cancer growth and unnecessary procedures. The clinical trial has had three participants but intends to test 25 patients, completing the trial within a year.